Oncolytic adenovirus-mediated E1A gene therapy induces tumor-cell apoptosis and reduces tumor angiogenesis leading to inhibition of hepatocellular carcinoma growth in animal model

Cancer Biotherapy and Radiopharmaceuticals

Volumn 21, Issue 3, 2006, Pages 225-234

  Ye, Zhenmin ^a,b   Wang, Xiaohua ^a   Hao, Siguo ^b   Zhong, Jiang ^c   Xiang, Jim ^b   Yang, Jicheng ^a  

^a SOOCHOW UNIVERSITY   (China)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c FUDAN UNIVERSITY   (China)

Author keywords

Angiogenesis; Apoptosis; E1A gene therapy; Hepatocellular carcinoma; Oncolytic adenovirus

Indexed keywords

ADENOVIRUS VECTOR; CASPASE 3; CD34 ANTIGEN; E1A PROTEIN; FAS ANTIGEN; ONCOLYTIC VIRUS; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; SURVIVIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER MODEL; CELL STRAIN HEPG2; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS RECOMBINANT;

ADENOVIRUS E1A PROTEINS; ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; ONCOLYTIC VIRUSES;

EID: 33746339977     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2006.21.225     Document Type: Article

References (55)

1. Zhu AX. Hepatocellular carcinoma: Are we making progress? Cancer Invest 2003;21(3):418.
2. Llovet JM, Beaugrand M. Hepatocellular carcinoma: Present status and future prospects. J Hepatol 2003;38(Suppl 1):S136.
3. Venook AP. Treatment of hepatocellular carcinoma: Too many options? J Clin Oncol 1994;12(6):1323.
4. Sugioka A, Tsuzuki T, Kanai T. Postresection prognosis of patients with hepatocellular carcinoma. Surgery 1993;113(6):612.
5. Llovet JM, Sala M, Bruix J. Nonsurgical treatment of hepatocellular carcinoma. Liver Transpl 2000;6(6 Suppl 2):S11.
6. Ruiz J, Qian C, Drozdzik M, et al. Gene therapy of viral hepatitis and hepatocellular carcinoma. J Viral Hepat 1999;6(1):17.
7. Qian C, Drozdzik M, Caselmann WH, et al. The potential of gene therapy in the treatment of hepatocellular carcinoma. J Hepatol 2000;32(2):344.
8. Mitry RR, Mansour MR, Havlik R, et al. Gene therapy for liver tumours. Adv Exp Med Biol 2000;465:193.
9. Vile RG, Russell SJ, Lemoine NR. Cancer gene therapy: Hard lessons and new courses. Gene Ther 2000;7(1):2.
10. Roth JA, Cristiano RJ. Gene therapy for cancer: What have we done and where are we going? J Natl Cancer Inst 1997;89(1):21.
11. Runnebaum IB. Basics of cancer gene therapy. Anticancer Res 1997;17(4B):2887.
12. Somasundaram K, El-Deiry WS. Inhibition of p53-mediated transactivation and cell-cycle arrest by E1A through its p300/CBP-interacting region. Oncogene 1997;14(9):1047.
13. Gallimore PH, Turnell AS. Adenovirus E1A: Remodelling the host cell, a life or death experience. Oncogene 2001;20(54):7824.
14. Mymryk JS. Tumour suppressive properties of the adenovirus 5 E1A oncogene. Oncogene 1996;13(8):1581.
15. Alemany R, Balague C, Curiel DT. Replicative adenoviruses for cancer therapy. Nat Biotechnol 2000; 18(7):723.
16. Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996;274(5286):373.
17. Nemunaitis J, Cunningham C, Buchanan A, et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: Safety, feasibility, and biological activity. Gene Ther 2001;8(10):746.
18. Nemunaitis J, Ganly I, Khuri F, et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial. Cancer Res 2000;60(22):63-59.
19. Hortobagyi GN, Ueno NT, Xia W, et al. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: A phase I clinical trial. J Clin Oncol 2001;19(14):3422.
20. Villaret D, Glisson B, Kenady D, et al. A multicenter phase II study of tgDCC-E1A for the intratumoral treatment of patients with recurrent head and neck squamous cell carcinoma. Head Neck 2002;24(7):661.
21. Frisch SM, Mymryk JS. Adenovirus-5 E1A: Paradox and paradigm. Nat Rev Mol Cell Biol 2002;3(6): 441.
22. Cheng WS, Dzojic H, Nilsson B, et al. An oncolytic conditionally replicating adenovirus for hormone-dependent and hormone-independent prostate cancer. Cancer Gene Ther 2006;13(1):13.
23. Kumar R, Fidler IJ. Angiogenic molecules and cancer metastasis. In Vivo 1998;12(1):27.
24. Mori A, Arii S, Furutani M, et al. Vascular endothelial growth factor-induced tumor angiogenesis and tumorigenicity in relation to metastasis in a HT1080 human fibrosarcoma cell model. Int J Cancer 1999;80(5):738.
25. Stabenow E, Tavares MR, Ab'Saber AM, et al. Angiogenesis as an indicator of metastatic potential in papillary thyroid carcinoma. Clinics 2005;60(3):233.
26. Wu HP, Feng GS, Liang HM, et al. Vascular endothelial growth factor antisense oligodeoxynucleotides with lipiodol in arterial embolization of liver cancer in rats. World J Gastroenterol 2004;10(6):813.
27. He TC, Zhou S, da Costa LT, et al. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998;95(5):2509.
28. Kim J, Lee B, Kim JS, et al. Antitumoral effects of recombinant adenovirus YKL-1001, conditionally replicating in alpha-fetoprotein-producing human liver cancer cells. Cancer Lett 2002;180(1):23.
29. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88(3):323.
30. Owen-Schaub LB, Zhang W, Cusack JC, et al. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 1995;15(6):3032.
31. Chi TY, Chen GG, Lai PB. Eicosapentaenoic acid induces Fas-mediated apoptosis through a p53-dependent pathway in hepatoma cells. Cancer J 2004;10(3):190.
32. Jaattela M. Escaping cell death: Survival proteins in cancer. Exp Cell Res 1999;248(1):30.
33. Kawasaki H, Altieri DC, Lu CD, et al. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998;58(22):5071.
34. Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998;58(23):5315.
35. Conway EM, Pollefeyt S, Steiner-Mosonyi M, et al. Deficiency of survivin in transgenic mice exacerbates Fas-induced apoptosis via mitochondrial pathways. Gastroenterology 2002;123(2):619.
36. Asanuma K, Tsuji N, Endoh T, et al. Survivin enhances Fas ligand expression via upregulation of specificity protein 1-mediated gene transcription in colon cancer cells. J Immunol 2004;172(6):3922.
37. Fimognari C, Nusse M, Cesari R, et al. Growth inhibition, cell-cycle arrest, and apoptosis in human T-cell leukemia by the isothiocyanate sulforaphane. Carcinogenesis 2002;23(4):581.
38. Altieri DC. Survivin, versatile modulation of cell division, and apoptosis in cancer. Oncogene 2003;22(53):8581.
39. Zhou Z, Zhou RR, Guan H, et al. E1A gene therapy inhibits angiogenesis in a Ewing's sarcoma animal model. Mol Cancer Ther 2003;2(12):1313.
40. Gasparini G. Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 2000;5(Suppl 1):37.
41. Vieira SC, Silva BB, Pinto GA, et al. CD34 as a marker for evaluating angiogenesis in cervical cancer. Pathol Res Pract 2005;201(4):313.
42. Ashkenazi A, Dixit VM. Death receptors: Signaling and modulation. Science 1998;281(5381):1305.
43. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5(2):157.
44. Cook JL, May DL, Lewis AM, Jr., et al. Adenovirus E1A gene induction of susceptibility to lysis by natural killer cells and activated macrophages in infected rodent cells. J Virol 1987;61(11):3510.
45. Cook JL, Routes BA, Walker TA, et al. E1A oncogene induction of cellular susceptibility to killing by cytolytic lymphocytes through target cell sensitization to apoptotic injury. Exp Cell Res 1999;251(2):414.
46. Routes JM, Cook JL. E1A gene expression induces susceptibility to killing by NK cells following immortalization but not adenovirus infection of human cells. Virology 1995;210(2):421.
47. Chang JY, Xia W, Shao R, et al. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer. Oncogene 1997;14(5):561.
48. Yu D, Hung MC. The erbB2 gene as a cancer therapeutic target and the tumor- and metastasis-suppressing function of E1A. Cancer Metastasis Rev 1998; 17(2):195.
49. Shisler J, Duerksen-Hughes P, Hermiston TM, et al. Induction of susceptibility to tumor necrosis factor by E1A is dependent on binding to either p300 or p105-Rb and induction of DNA synthesis. J Virol 1996;70(1):68.
50. Shao R, Karunagaran D, Zhou BP, et al. Inhibition of nuclear factor-kappaB activity is involved in E1A-mediated sensitization of radiation-induced apoptosis. J Biol Chem 1997;272(52):32739.
51. Cook JL, Potter TA, Bellgrau D, et al. E1A oncogene expression in target cells induces cytolytic susceptibility at a postrecognition stage in the interaction with killer lymphocytes. Oncogene 1996;13(4):833.
52. Duerksen-Hughes P, Wold WS, Gooding LR. Adenovirus E1A renders infected cells sensitive to cytolysis by tumor necrosis factor. J Immunol 1989;143(12):4193.
53. Routes JM, Ryan S, Clase A, et al. Adenovirus E1A oncogene expression in tumor cells enhances killing by TNF-related apoptosis-inducing ligand (TRAIL). J Immunol 2000;165(8):4522.
54. Ren XW, Liang M, Meng X, et al. A tumor-specific conditionally replicative adenovirus vector expressing TRAIL for gene therapy of hepatocellular carcinoma. Cancer Gene Ther 2006;13:159.
55. Guo W, Zhu H, Zhang L, et al. Combination effect of oncolytic adenovirotherapy and TRAIL gene therapy in syngeneic murine breast cancer models. Cancer Gene Ther 2006;13(1):82.